The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
